Second Distress Mechanism of Repaired Potholes and Performance Evaluation of Repair Techniques from Multiple Perspectives
Wei Zhang, Shan Zuo, Ke Zhang, Zongzhi Liu
cn (code pays fourni par la source)
1 citation
Coatings
Zongzhi Liu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
272Publications signalées
4649Citations signalées
3Affiliations récentes
Les institutions déclarées
Les domaines associés
Lung Cancer Treatments and MutationsRNA modifications and cancerCytokine Signaling Pathways and InteractionsHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies
Les publications récentes
Protein-truncating variants in UQCRC1 are associated with Parkinson’s disease: evidence from half-million people
Xiaoxi Jing, Zongzhi Liu, Wen Li, K. Ma et autres
cz, cn, gb (code pays fourni par la source)
3 citations
npj Parkinson s Disease
Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing
Kyeryoung Lee, Zongzhi Liu, Qing Huang, David Corrigan et autres
us (code pays fourni par la source)
2 citations
JCO Clinical Cancer Informatics
Identification of nitric oxide-mediated necroptosis as the predominant death route in Parkinson’s disease
Ting Zhang, Wenjing Rui, Yue Sun, Yunyun Tian et autres
cn (code pays fourni par la source)
11 citations
Molecular Biomedicine
Figure S1 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Table S4 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Table S3 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Table S4 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Figure S7 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Figure S8 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Figure S7 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
Figure S6 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.